A Randomized Trial to Assess the Acceleration of Viral Clearance by the Combination Favipiravir/Ivermectin/Niclosamide in Mild-to-Moderate COVID-19 Adult Patients (FINCOV)
M.D Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, M.D Panisadee Avirutnan, Ph.D. e Kunlakanya Jitobaom, Prasert Auewarakul
doi:10.1016/j.jiph.2024.03.030
Background: The efficacy of the viral clearance and clinical outcomes of favipiravir (FPV) in outpatients being treated for coronavirus disease 2019 (COVID-19) is unclear. Ivermectin (IVM), niclosamide (NCL), and FPV demonstrated synergistic effects in vitro for exceed 78% inhibiting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) replication. Methods: A phase 2, open-label, 1:1, randomized, controlled trial was conducted on Thai patients with mild-to-moderate COVID-19 who received either combination FPV/IVM/NCL therapy or FPV alone to assess the rate of viral clearance among individuals with mild-to-moderate COVID-19. Results: Sixty non-high-risk comorbid patients with mild-to-moderate COVID-19 were randomized; 30 received FPV/IVM/NCL, and 30 received FPV alone. Mixed-effects multiple linear regression analysis of the cycle threshold value from SARS-CoV-2 PCR demonstrated no statistically significant differences in viral clearance rates between the combined FPV/IVM/NCL therapy group and the FPV-alone group. World Health Organization Clinical Progression scores and symptomatic improvement did not differ between arms on days 3, 6, and 10, and no adverse J o u r n a l P r e -p r o o f events were reported. No patients required hospitalization, intensive care unit admission, or supplemental oxygen or died within 28 days. C-reactive protein on day 3 was lower in the FPV/IVM/NCL group.
Conclusion: Viral clearance rates did not differ significantly between the FPV/IVM/NCL combination therapy and FPV-alone groups of individuals with mild-to-moderate COVID-19, although the combined regimen demonstrated a synergistic effect in vitro. No discernible clinical benefit was observed. Further research is required to explore the potential benefits of FVP beyond its antiviral effects.
Conflicts of Interest The authors declare that they have no competing interests.
J o u r n a l P r e -p r o o f
References
Abd-Elsalam, Noor, Badawi, Khalaf, Esmail et al., Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study, J Med Virol,
doi:10.1002/jmv.27122Abdulamir, Gorial, Saadi, Maulood, Hashim et al., A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management, Ann Med Surg (Lond),
doi:10.1016/j.amsu.2021.102779Audus, Knaub, Guillot, Schaeffer, The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells, Vet Res Commun,
doi:10.1007/bf01839186Backer, Sjöbring, Sonne, Weiss, Hostrup et al., A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19, Lancet Reg Health Eur,
doi:10.1016/j.lanepe.2021.100084Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med,
doi:10.1056/NEJMoa2116044Bhimraj, Morgan, Shumaker, Lavergne, Baden et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, Clin Infect Dis,
doi:10.1093/cid/ciaa478Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Buonfrate, Chesini, Martini, Roncaglioni, Fernandez et al., High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, doubleblind, multicentre, phase II, dose-finding, proof-of-concept clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2021.106516Cairns, Dulko, Griffiths, Golan, Cohen et al., Efficacy of niclosamide vs placebo in sars-cov-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: A phase 2 randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.44942Doi, Ando, Kuwatsuka, Ishihara, Favipiravir, Favipiravir Observational Study Interim Report 3
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther,
doi:10.1002/cpt.1844Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad, Ser B,
doi:10.2183/pjab.93.027Galan, Santos, Asato, Araújo, De Lima Moreira et al., Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health,
doi:10.1080/20477724.2021.1890887Golan, Campos, Woolson, Cilla, Hanabergh et al., Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial, Clin Infect Dis,
doi:10.1093/cid/ciac712Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and J o u r n a l P r e -p r o o f meta-analysis of clinical trials, Sci Rep,
doi:10.1038/s41598-021-90551-6Irie, Nakagawa, Fujita, Tamura, Eto et al., Population pharmacokinetics of favipiravir in patients with COVID-19, CPT Pharmacometrics Syst Pharmacol,
doi:10.1002/psp4.12685Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis,
doi:10.1093/cid/ciaa1176Jeon, Ko, Lee, Choi, Byun et al., Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob Agents Chemother,
doi:10.1128/aac.00819-20Jitobaom, Boonarkart, Manopwisedjaroen, Punyadee, Borwornpinyo et al., Favipiravir and ivermectin show in vitro synergistic antiviral activity against SARS-CoV-2, Acta Virologica
Jitobaom, Boonarkart, Manopwisedjaroen, Punyadee, Borwornpinyo et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacol Toxicol,
doi:10.1186/s40360-022-00580-8Lim, Hor, Tay, Jelani, Tan et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-TECH randomized clinical trial, JAMA Intern Med,
doi:10.1001/jamainternmed.2022.0189López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial, JAMA,
doi:10.1001/jama.2021.3071.JournalPre-proofMarshall, Murthy, Diaz, Adhikari, Angus et al., A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30483-7Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial, J Infect Chemother,
doi:10.1016/j.jiac.2021.08.021Naggie, Boulware, Lindsell, Stewart, Gentile et al., Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial, JAMA,
doi:10.1001/jama.2022.18590Naggie, Boulware, Lindsell, Stewart, Slandzicki et al., Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: A randomized clinical trial, JAMA,
doi:10.1001/jama.2023.1650Peña-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br J Clin Pharmacol,
doi:10.1111/bcp.14476Ravikirti, Pattadar, Raj, Agarwal, Biswas, Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: A double-blind randomized placebo controlled trial in Eastern India, J Pharm Pharm Sci,
doi:10.18433/jpps32105.JournalPre-proofReis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2115869Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and metaanalysis, Virol J,
doi:10.1186/s12985-020-01412-zSingh, Weiss, Goodman, Fisk, Kulkarni et al., Niclosamide-A promising treatment for COVID-19, Br J Pharmacol,
doi:10.1111/bph.15843Siripongboonsitti, Muadchimkaew, Tawinprai, Issaranon, Meepholkij et al., Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV), Sci Rep,
doi:10.1038/s41598-023-42195-xSiripongboonsitti, Tawinprai, Cheirsilpa, Ungtrakul, Krisorakun et al., The real-world clinical outcomes of favipiravir treatment with telemedicine monitoring in preventing disease progression in mild to moderate COVID-19 patients: a retrospective cohort study, Medicina,
doi:10.3390/medicina59061098Trivedi, Lee, Meibohm, Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives, Expert Rev Clin Pharmacol,
doi:10.1586/ecp.13.6Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Inter J Infect Dis,
doi:10.1016/j.ijid.2020.11.142Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis,
doi:10.1186/s12879-021-06348-5Watson, Kissler, Day, Grad, White, Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies, Antimicrob Agents Chemother,
doi:10.1128/aac.00192-22Watson, Kisslerc, Daya, Gradc, Whitea, Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs, MedRxiv
{ 'indexed': {'date-parts': [[2024, 4, 3]], 'date-time': '2024-04-03T01:19:56Z', 'timestamp': 1712107196023},
'reference-count': 52,
'publisher': 'Elsevier BV',
'issue': '5',
'license': [ { 'start': { 'date-parts': [[2024, 5, 1]],
'date-time': '2024-05-01T00:00:00Z',
'timestamp': 1714521600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2024, 3, 27]],
'date-time': '2024-03-27T00:00:00Z',
'timestamp': 1711497600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'funder': [ { 'DOI': '10.13039/501100016062',
'name': 'National Health Foundation',
'doi-asserted-by': 'publisher'},
{ 'DOI': '10.13039/100016175',
'name': 'Chulabhorn Royal Academy',
'doi-asserted-by': 'publisher'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 5]]},
'DOI': '10.1016/j.jiph.2024.03.030',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T07:40:22Z', 'timestamp': 1711698022000},
'page': '897-905',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'A randomized trial to assess the acceleration of viral clearance by the combination '
'Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)',
'prefix': '10.1016',
'volume': '17',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7256-9982',
'authenticated-orcid': False,
'given': 'Taweegrit',
'family': 'Siripongboonsitti',
'sequence': 'first',
'affiliation': []},
{'given': 'Kriangkrai', 'family': 'Tawinprai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Panisadee', 'family': 'Avirutnan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kunlakanya', 'family': 'Jitobaom', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4745-4291',
'authenticated-orcid': False,
'given': 'Prasert',
'family': 'Auewarakul',
'sequence': 'additional',
'affiliation': []}],
'member': '78',
'reference': [ { 'issue': '15',
'key': '10.1016/j.jiph.2024.03.030_bib1',
'doi-asserted-by': 'crossref',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '6',
'key': '10.1016/j.jiph.2024.03.030_bib2',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'article-title': 'Molnupiravir for oral treatment of Covid-19 in Nonhospitalized Patients',
'volume': '386',
'author': 'Jayk Bernal',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib3',
'unstructured': 'U.S. Food and Drug Administration, FDA NEWS RELEASE, Coronavirus '
'(COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of '
'COVID-19 2021 [updated December 22, 2021. Available from: '
'〈https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19〉].'},
{ 'issue': '2',
'key': '10.1016/j.jiph.2024.03.030_bib4',
'doi-asserted-by': 'crossref',
'first-page': '242',
'DOI': '10.1002/cpt.1844',
'article-title': 'Favipiravir: pharmacokinetics and concerns about clinical trials for '
'2019‐nCoV infection',
'volume': '108',
'author': 'Du',
'year': '2020',
'journal-title': 'Clin Pharm Ther'},
{ 'issue': '7',
'key': '10.1016/j.jiph.2024.03.030_bib5',
'doi-asserted-by': 'crossref',
'first-page': '449',
'DOI': '10.2183/pjab.93.027',
'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase',
'volume': '93',
'author': 'Furuta',
'year': '2017',
'journal-title': 'Proc Jpn Acad, Ser B'},
{ 'issue': '10',
'key': '10.1016/j.jiph.2024.03.030_bib6',
'doi-asserted-by': 'crossref',
'first-page': '1192',
'DOI': '10.1016/j.eng.2020.03.007',
'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label '
'control study',
'volume': '6',
'author': 'Cai',
'year': '2020',
'journal-title': 'Engineering'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib7',
'article-title': 'Favipiravir versus arbidol for COVID-19: a randomized clinical trial',
'author': 'Chen',
'year': '2020',
'journal-title': 'MedRxiv'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib8',
'article-title': 'AVIFAVIR for treatment of patients with moderate coronavirus disease '
'2019 (COVID-19): interim results of a phase II/III multicenter '
'randomized clinical trial',
'author': 'Ivashchenko',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib9',
'unstructured': 'Department of Medical Service. Clinical Practice Guideline to Diagnosis, '
'Treatment and Prevention COVID-19 for Physician and Health Care '
'Provider, 21 July 2021 [Available from: '
'https://covid19.dms.go.th/Content/Select_Landding_page?contentId=139].'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib10',
'article-title': 'Role of favipiravir in the treatment of COVID-19',
'author': 'Joshi',
'year': '2020',
'journal-title': 'Inter J Infect Dis'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib11',
'article-title': 'Fujita Health University',
'volume': '3',
'author': 'Doi',
'year': '2021',
'journal-title': 'Favipiravir Obs Study Interim Rep'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib12',
'doi-asserted-by': 'crossref',
'first-page': '62',
'DOI': '10.1016/j.ijid.2020.11.142',
'article-title': 'Efficacy and safety of favipiravir, an oral RNA-dependent RNA '
'polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, '
'comparative, open-label, multicenter, phase 3 clinical trial',
'volume': '103',
'author': 'Udwadia',
'year': '2021',
'journal-title': 'Inter J Infect Dis'},
{ 'issue': '6',
'key': '10.1016/j.jiph.2024.03.030_bib13',
'article-title': 'The real-world clinical outcomes of favipiravir treatment with '
'telemedicine monitoring in preventing disease progression in mild to '
'moderate COVID-19 patients: a retrospective cohort study',
'volume': '59',
'author': 'Siripongboonsitti',
'year': '2023',
'journal-title': 'Med (Kaunas)'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.03.030_bib14',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/s41598-023-42195-x',
'article-title': 'Favipiravir treatment in non-severe COVID-19: promising results from '
'multicenter propensity score-matched study (FAVICOV)',
'volume': '13',
'author': 'Siripongboonsitti',
'year': '2023',
'journal-title': 'Sci Rep'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.03.030_bib15',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1038/s41598-021-90551-6',
'article-title': 'The efficacy and safety of Favipiravir in treatment of COVID-19: A '
'systematic review and meta-analysis of clinical trials',
'volume': '11',
'author': 'Hassanipour',
'year': '2021',
'journal-title': 'Sci Rep'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.03.030_bib16',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1186/s12985-020-01412-z',
'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 '
'treatment: a rapid systematic review and meta-analysis',
'volume': '17',
'author': 'Shrestha',
'year': '2020',
'journal-title': 'Virol J'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib17',
'article-title': 'Favipiravir in patients with early mild-to-moderate COVID-19: a '
'randomized controlled trial',
'author': 'Golan',
'year': '2022',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '10',
'key': '10.1016/j.jiph.2024.03.030_bib18',
'doi-asserted-by': 'crossref',
'first-page': '1161',
'DOI': '10.1002/psp4.12685',
'article-title': 'Population pharmacokinetics of favipiravir in patients with COVID-19',
'volume': '10',
'author': 'Irie',
'year': '2021',
'journal-title': 'CPT Pharmacomet Syst Pharm'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib19',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2020.104787',
'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 '
'in vitro',
'volume': '178',
'author': 'Caly',
'year': '2020',
'journal-title': 'Antivir Res'},
{ 'issue': '18',
'key': '10.1016/j.jiph.2024.03.030_bib20',
'doi-asserted-by': 'crossref',
'first-page': '1721',
'DOI': '10.1056/NEJMoa2115869',
'article-title': 'Effect of early treatment with ivermectin among patients with COVID-19',
'volume': '386',
'author': 'Reis',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '2',
'key': '10.1016/j.jiph.2024.03.030_bib21',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2021.106516',
'article-title': 'High-dose ivermectin for early treatment of COVID-19 (COVER study): a '
'randomised, double-blind, multicentre, phase II, dose-finding, '
'proof-of-concept clinical trial',
'volume': '59',
'author': 'Buonfrate',
'year': '2022',
'journal-title': 'Int J Antimicrob Agents'},
{ 'issue': '12',
'key': '10.1016/j.jiph.2024.03.030_bib22',
'doi-asserted-by': 'crossref',
'first-page': '1743',
'DOI': '10.1016/j.jiac.2021.08.021',
'article-title': 'Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): '
'a single-centre randomized, placebo-controlled trial',
'volume': '27',
'author': 'Mohan',
'year': '2021',
'journal-title': 'J Infect Chemother'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib23',
'doi-asserted-by': 'crossref',
'first-page': '343',
'DOI': '10.18433/jpps32105',
'article-title': 'Evaluation of ivermectin as a potential treatment for mild to moderate '
'COVID-19: a double-blind randomized placebo controlled trial in Eastern '
'India',
'volume': '24',
'author': 'Ravikirti',
'year': '2021',
'journal-title': 'J Pharm Pharm Sci'},
{ 'issue': '11',
'key': '10.1016/j.jiph.2024.03.030_bib24',
'doi-asserted-by': 'crossref',
'first-page': '888',
'DOI': '10.1001/jama.2023.1650',
'article-title': 'Effect of higher-dose ivermectin for 6 days vs placebo on time to '
'sustained recovery in outpatients with COVID-19: A randomized clinical '
'trial',
'volume': '329',
'author': 'Naggie',
'year': '2023',
'journal-title': 'JAMA'},
{ 'issue': '16',
'key': '10.1016/j.jiph.2024.03.030_bib25',
'doi-asserted-by': 'crossref',
'first-page': '1595',
'DOI': '10.1001/jama.2022.18590',
'article-title': 'Effect of ivermectin vs placebo on time to sustained recovery in '
'outpatients with mild to moderate COVID-19: A randomized clinical trial',
'volume': '328',
'author': 'Naggie',
'year': '2022',
'journal-title': 'JAMA'},
{ 'issue': '4',
'key': '10.1016/j.jiph.2024.03.030_bib26',
'doi-asserted-by': 'crossref',
'first-page': '235',
'DOI': '10.1080/20477724.2021.1890887',
'article-title': 'Phase 2 randomized study on chloroquine, hydroxychloroquine or '
'ivermectin in hospitalized patients with severe manifestations of '
'SARS-CoV-2 infection',
'volume': '115',
'author': 'Galan',
'year': '2021',
'journal-title': 'Pathog Glob Health'},
{ 'issue': '10',
'key': '10.1016/j.jiph.2024.03.030_bib27',
'doi-asserted-by': 'crossref',
'first-page': '5833',
'DOI': '10.1002/jmv.27122',
'article-title': 'Clinical study evaluating the efficacy of ivermectin in COVID-19 '
'treatment: a randomized controlled study',
'volume': '93',
'author': 'Abd-Elsalam',
'year': '2021',
'journal-title': 'J Med Virol'},
{ 'issue': '4',
'key': '10.1016/j.jiph.2024.03.030_bib28',
'doi-asserted-by': 'crossref',
'first-page': '426',
'DOI': '10.1001/jamainternmed.2022.0189',
'article-title': 'Efficacy of ivermectin treatment on disease progression among adults '
'with mild to moderate COVID-19 and comorbidities: The I-TECH randomized '
'clinical trial',
'volume': '182',
'author': 'Lim',
'year': '2022',
'journal-title': 'JAMA Intern Med'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.03.030_bib29',
'doi-asserted-by': 'crossref',
'first-page': '635',
'DOI': '10.1186/s12879-021-06348-5',
'article-title': 'Ivermectin to prevent hospitalizations in patients with COVID-19 '
'(IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial',
'volume': '21',
'author': 'Vallejos',
'year': '2021',
'journal-title': 'BMC Infect Dis'},
{ 'issue': '14',
'key': '10.1016/j.jiph.2024.03.030_bib30',
'doi-asserted-by': 'crossref',
'first-page': '1426',
'DOI': '10.1001/jama.2021.3071',
'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults '
'with mild COVID-19: a randomized clinical trial',
'volume': '325',
'author': 'López-Medina',
'year': '2021',
'journal-title': 'JAMA'},
{ 'issue': '7',
'key': '10.1016/j.jiph.2024.03.030_bib31',
'doi-asserted-by': 'crossref',
'first-page': '599',
'DOI': '10.1056/NEJMoa2201662',
'article-title': 'Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19',
'volume': '387',
'author': 'Bramante',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '13',
'key': '10.1016/j.jiph.2024.03.030_bib32',
'doi-asserted-by': 'crossref',
'first-page': '3250',
'DOI': '10.1111/bph.15843',
'article-title': 'Niclosamide-a promising treatment for COVID-19',
'volume': '179',
'author': 'Singh',
'year': '2022',
'journal-title': 'Br J Pharm'},
{ 'issue': '7',
'key': '10.1016/j.jiph.2024.03.030_bib33',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/AAC.00819-20',
'article-title': 'Identification of antiviral drug candidates against SARS-CoV-2 from '
'FDA-approved drugs',
'volume': '64',
'author': 'Jeon',
'year': '2020',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'issue': '2',
'key': '10.1016/j.jiph.2024.03.030_bib34',
'doi-asserted-by': 'crossref',
'DOI': '10.1001/jamanetworkopen.2021.44942',
'article-title': 'Efficacy of niclosamide vs placebo in sars-cov-2 respiratory viral '
'clearance, viral shedding, and duration of symptoms among patients with '
'mild to moderate COVID-19: A phase 2 randomized clinical trial',
'volume': '5',
'author': 'Cairns',
'year': '2022',
'journal-title': 'JAMA Netw Open'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib35',
'article-title': 'A randomised controlled trial of effectiveness and safety of '
'Niclosamide as add on therapy to the standard of care measures in '
'COVID-19 management',
'volume': '69',
'author': 'Abdulamir',
'year': '2021',
'journal-title': 'Ann Med Surg (Lond)'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.03.030_bib36',
'doi-asserted-by': 'crossref',
'first-page': '41',
'DOI': '10.1186/s40360-022-00580-8',
'article-title': 'Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug '
'combinations',
'volume': '23',
'author': 'Jitobaom',
'year': '2022',
'journal-title': 'BMC Pharm Toxicol'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib37',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/av.2023.12265',
'article-title': 'Favipiravir and ivermectin show in vitro synergistic antiviral activity '
'against SARS-CoV-2',
'volume': '67',
'author': 'Jitobaom',
'year': '2023',
'journal-title': 'Acta Virol'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib38',
'unstructured': 'European Medicines Agency, ICH: E6 (R2) Good Clinical '
'Practice–Scientific Guideline. 2016.'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib39',
'unstructured': 'WHO, Health in all policies: Helsinki statement. Framework for country '
'action. Health in all Policies Helsinki Statement Framework for Country '
'Action. 2014.'},
{ 'issue': '8',
'key': '10.1016/j.jiph.2024.03.030_bib40',
'doi-asserted-by': 'crossref',
'first-page': 'e192',
'DOI': '10.1016/S1473-3099(20)30483-7',
'article-title': 'A minimal common outcome measure set for COVID-19 clinical research',
'volume': '20',
'author': 'Marshall',
'year': '2020',
'journal-title': 'Lancet Infect Dis'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib41',
'unstructured': 'COVID-19 Treatment Guidelines Panel, Coronavirus Disease 2019 (COVID-19) '
'Treatment Guidelines 2020 [19 November 2022]. Available from: '
'〈https://www.covid19treatmentguidelines.nih.gov/〉.'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib42',
'article-title': 'Infectious diseases society of america guidelines on the treatment and '
'management of patients with COVID-19',
'author': 'Bhimraj',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '7',
'key': '10.1016/j.jiph.2024.03.030_bib43',
'doi-asserted-by': 'crossref',
'DOI': '10.1128/aac.00192-22',
'article-title': 'Characterizing SARS-CoV-2 viral clearance kinetics to improve the '
'design of antiviral pharmacometric studies',
'volume': '66',
'author': 'Watson',
'year': '2022',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'issue': '2',
'key': '10.1016/j.jiph.2024.03.030_bib44',
'doi-asserted-by': 'crossref',
'first-page': '159',
'DOI': '10.1586/ecp.13.6',
'article-title': 'Applications of pharmacometrics in the clinical development and '
'pharmacotherapy of anti-infectives',
'volume': '6',
'author': 'Trivedi',
'year': '2013',
'journal-title': 'Expert Rev Clin Pharm'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib45',
'unstructured': 'Watson J.A., Kisslerc S., Daya N.P., Gradc Y., Whitea N.J. Optimal '
'design for phase 2 studies of SARS-CoV-2 antiviral drugs. MedRxiv 2021.'},
{ 'issue': '3',
'key': '10.1016/j.jiph.2024.03.030_bib46',
'doi-asserted-by': 'crossref',
'first-page': '1589',
'DOI': '10.1111/bcp.14476',
'article-title': 'Pharmacokinetic considerations on the repurposing of ivermectin for '
'treatment of COVID-19',
'volume': '87',
'author': 'Peña-Silva',
'year': '2021',
'journal-title': 'Br J Clin Pharm'},
{ 'issue': '5',
'key': '10.1016/j.jiph.2024.03.030_bib47',
'doi-asserted-by': 'crossref',
'first-page': '365',
'DOI': '10.1007/BF01839186',
'article-title': 'The effect of protein binding on ivermectin uptake by bovine brain '
'microvessel endothelial cells',
'volume': '16',
'author': 'Audus',
'year': '1992',
'journal-title': 'Vet Res Commun'},
{ 'key': '10.1016/j.jiph.2024.03.030_bib48',
'article-title': 'A randomized, double-blind, placebo-controlled phase 1 trial of inhaled '
'and intranasal niclosamide: a broad spectrum antiviral candidate for '
'treatment of COVID-19',
'volume': '4',
'author': 'Backer',
'year': '2021',
'journal-title': 'Lancet Reg Health Eur'},
{ 'issue': '2',
'key': '10.1016/j.jiph.2024.03.030_bib49',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pone.0246803',
'article-title': 'Development and evaluation of inhalable composite niclosamide-lysozyme '
'particles: a broad-spectrum, patient-adaptable treatment for '
'coronavirus infections and sequalae',
'volume': '16',
'author': 'Brunaugh',
'year': '2021',
'journal-title': 'PLoS One'},
{ 'issue': '6',
'key': '10.1016/j.jiph.2024.03.030_bib50',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pone.0198389',
'article-title': 'A phase I study of niclosamide in combination with enzalutamide in men '
'with castration-resistant prostate cancer',
'volume': '13',
'author': 'Schweizer',
'year': '2018',
'journal-title': 'PLoS One'},
{ 'issue': '8',
'key': '10.1016/j.jiph.2024.03.030_bib51',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pone.0202709',
'article-title': 'Correction: a phase I study of niclosamide in combination with '
'enzalutamide in men with castration-resistant prostate cancer',
'volume': '13',
'author': 'Schweizer',
'year': '2018',
'journal-title': 'PLoS One'},
{ 'issue': '12',
'key': '10.1016/j.jiph.2024.03.030_bib52',
'doi-asserted-by': 'crossref',
'first-page': '8195',
'DOI': '10.1007/s11033-021-06770-7',
'article-title': 'Niclosamide for Covid-19: bridging the gap',
'volume': '48',
'author': 'Al-Kuraishy',
'year': '2021',
'journal-title': 'Mol Biol Rep'}],
'container-title': 'Journal of Infection and Public Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124001060?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124001060?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2024, 4, 2]],
'date-time': '2024-04-02T16:46:57Z',
'timestamp': 1712076417000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1876034124001060'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 5]]},
'references-count': 52,
'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2024, 5]]}},
'alternative-id': ['S1876034124001060'],
'URL': 'http://dx.doi.org/10.1016/j.jiph.2024.03.030',
'relation': {},
'ISSN': ['1876-0341'],
'subject': [ 'Infectious Diseases', 'Public Health, Environmental and Occupational Health',
'General Medicine'],
'container-title-short': 'Journal of Infection and Public Health',
'published': {'date-parts': [[2024, 5]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'A randomized trial to assess the acceleration of viral clearance by the '
'combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 '
'adult patients (FINCOV)',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Journal of Infection and Public Health',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.jiph.2024.03.030',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2024 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin '
'Abdulaziz University for Health Sciences.',
'name': 'copyright',
'label': 'Copyright'}]}
